Friday, July 10, 2026

pharma · Head and Neck Neoplasms · Rheumatoid Arthritis

Chinese University of

Chinese University of is a pharma organization headquartered in CN. Primary therapeutic focus areas include Head and Neck Neoplasms, Rheumatoid Arthritis, Rare Tumor, Essential Hypertension, Primary Esophageal Motility D

CN HQ
NMPA registrant Type
Company details
Status
Public
HQ
CN
Programs
42
Drugs
55
Patents
0
Clinical program

Sodium valproate

Approved · small molecule · Epilepsy

Sodium valproate for Epilepsy is a Approved program (small_molecule) at Chinese University of Hong Kong with 1 ClinicalTrials.gov record(s).

Internal code CRE-2004.399

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Chinese University of Hong Kong
Phase
Approved
Modality
small_molecule
Indication
Epilepsy
Status
active
Trials
1